SIMS Portex Limited Hythe, Kent, Anglicko (GB) Spojené kráľovstvo Veľkej Británie a Severného Írska - rezultati pretrage

Europska Unija - hrvatski - EMA (European Medicines Agency)

cerezyme

sanofi b.v. - imigluceraza - gaucherova bolest - drugi gastrointestinalni trakt i metabolizam, lijekovi, - cerezyme (imiglucerase) je indiciran za uporabu kao dugoročne nadomjesne enzimske terapije u bolesnika s dijagnosticiranim sobe-neuronopathic (tip 1) ili kronični neuronopathic (tip 3) gaucherove bolesti koji pokazuju klinički značajnim nonneurological manifestacije bolesti. ne-manifestacijama neuroloških bolesti Гоше uključuje jedan ili više od sljedećih uvjeta:anemija nakon isključenja drugih razloga kao što su bolest glačalo deficiencythrombocytopeniabone nakon isključivanja drugih uzroka, kao što su vitamin d deficiencyhepatomegaly ili спленомегалия.

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

cerezyme 400 jedinica/1 bočica prašak za koncentrat za otopinu za infuziju

sanofi d.o.o. - imigluceraza - prašak za koncentrat za otopinu za infuziju - 400 jedinica/1 bočica - 1 bočica sa praškom za koncentrat za infuziju sadrži: 400 u (40 jedinica/ml) imigluceraza

cerezyme 400 jedinica/1 bočica prašak za koncentrat za rastvor za infuziju

amicus pharma d.o.o. - imigluceraza - prašak za koncentrat za rastvor za infuziju - 400 jedinica/1 bočica - 1 bočica sa praškom za koncentrat za rastvor za infuziju sadrži: 400 u (40 jedinica/ml) imigluceraza

timolol farmavita 5 mg/1 ml kapi za oči , rastvor

farmavita d.o.o. sarajevo - timolol - kapi za oči , rastvor - 5 mg/1 ml - 1 ml kapi za oči, rastvora sadrži: 5 mg timolola (u obliku timololmaleata)

timolol alkaloid 5 mg/1 ml kapi za oči , rastvor

alkaloid d.o.o. sarajevo - timolol - kapi za oči , rastvor - 5 mg/1 ml - 1 ml kapi za oči, rastvora sadrži: 5 mg timolola (u obliku timololmaleata)

Europska Unija - hrvatski - EMA (European Medicines Agency)

hyrimoz

sandoz gmbh - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; arthritis, juvenile rheumatoid; crohn disease; skin diseases, papulosquamous - imunosupresivi - rheumatoid arthritishyrimoz in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hyrimoz može biti dano kao monoterapija u slučaju netolerancije метотрексата ili pri stalnom liječenju s metotreksat je nepraktično. Адалимумаб, kao što je prikazano, kako bi se smanjila brzina progresije oštećenja zglobova kao što se mjeri x-ray i poboljšati fizičku funkciju, prilikom raspoređivanja u kombinaciji s metotreksatom. juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritishyrimoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). hyrimoz može biti dano kao monoterapija u slučaju netolerancije метотрексата ili pri stalnom liječenju s metotreksat je nepraktično. Адалимумаб ne ima dugu povijest u bolesnika u dobi od manje od 2 godine. - enthesitis-related arthritishyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritis- ankylosing spondylitis (as)hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. - axial spondyloarthritis without radiographic evidence of ashyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. psoriatic arthritishyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Адалимумаб, kao što je prikazano, kako bi se smanjila brzina progresije periferne lezije zgloba, mjereno pomoću x-zraka u bolesnika s полиартикулярным mogućnost simetrične podtipovi bolesti i poboljšati tjelesne funkcije. psoriasishyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishyrimoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy. crohn’s diseasehyrimoz is indicated for treatment of moderately to severely active crohn’s disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehyrimoz is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies. paediatric ulcerative colitishyrimoz is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. ulcerative colitishyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishyrimoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

glaumol 5 mg/1 ml kapi za oči , rastvor

galenika d.o.o. - timolol - kapi za oči , rastvor - 5 mg/1 ml - 1 ml kapi za oči, rastvor sadrži: 5 mg timolol (u obliku timololmaleata)

duotrav 40 µg/1 ml+ 5 mg/1 ml kapi za oko, otopina

novartis ba d.o.o. - timolol, травопрост - kapi za oko, otopina - 40 µg/1 ml+ 5 mg/1 ml - 1 ml kapi za oko, otopine sadrži: 40 mcg travoprost i 5 mg timolol (u obliku timololmaleata)

normatin 6,83 mg/1 ml kapi za oči, rastvor

world medicine bosnia d.o.o. - timolol - kapi za oči, rastvor - 6,83 mg/1 ml - 1 ml kapi za oči, rastvora sadrži: 6,83 mg timolol maleata (što odgovara 5 mg timolola)

unitimolol 0,5 % 5 mg/1 ml kapi za oči , rastvor

tuzlafarm d.o.o. tuzla - timolol - kapi za oči , rastvor - 5 mg/1 ml - 1 ml kapi za oči, rastvora sadrži: 5 mg timolol (u obliku timolol maleata)